Giovanni Scambia

Summary

Affiliation: Catholic University
Country: Italy

Publications

  1. pmc Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Catholic University of Campobasso, Campobasso, Italy
    BMC Cancer 14:947. 2014
  2. pmc Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma
    Giuseppina Bonanno
    Department of Gynecology, Catholic University Med School, Rome, Italy
    J Transl Med 10:247. 2012
  3. pmc Long-term prospective longitudinal evaluation of emotional distress and quality of life in cervical cancer patients who remained disease-free 2-years from diagnosis
    Giovanna Mantegna
    Psycho Oncology Service, Catholic University, Campobasso, Italy
    BMC Cancer 13:127. 2013
  4. pmc MiR-200c and HuR in ovarian cancer
    Silvia Prislei
    Laboratory of Antineoplastic Pharmacology, Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome 00168, Italy
    BMC Cancer 13:72. 2013
  5. pmc Conservatively treated glassy cell carcinoma of the cervix
    Gabriella Ferrandina
    Department of Oncology, Catholic University, Campobasso, Rome, Italy
    World J Surg Oncol 6:92. 2008
  6. pmc Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures
    Giuseppina Bonanno
    Department of Gynecology, Catholic University Med School, and Department of Blood Transfusion and Cell Therapy, Azienda Ospedaliera S Camillo Forlanini, Rome, Italy
    J Transl Med 8:129. 2010
  7. pmc Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies
    Giuseppina Bonanno
    Department of Hematology, Catholic University Med, School, Rome, Italy
    J Transl Med 8:114. 2010
  8. pmc Solitary pancreatic lymph node metastasis from carcinoma of the breast: case report
    Giacomo Corrado
    Gynecologic Oncology Unit, Department of Oncology, Catholic University of the Sacred Heart, L, go A, Gemelli, 1 86100, Campobasso Italy
    Diagn Pathol 5:29. 2010
  9. pmc Interleukin-21 induces the differentiation of human umbilical cord blood CD34-lineage- cells into pseudomature lytic NK cells
    Giuseppina Bonanno
    Department of Gynaecology, Catholic University Medical School, Rome, Italy
    BMC Immunol 10:46. 2009
  10. pmc Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients
    Francesco Legge
    Gynecologic Oncology Unit, Catholic University of Campobasso, Italy
    BMC Cancer 11:214. 2011

Detail Information

Publications15

  1. pmc Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Catholic University of Campobasso, Campobasso, Italy
    BMC Cancer 14:947. 2014
    ..The aim of this multicenter, retrospective study was to evaluate the efficacy and safety of metronomic oral cyclophosphamide (MOC) in heavily treated, relapsed ovarian cancer (ROC) patients...
  2. pmc Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma
    Giuseppina Bonanno
    Department of Gynecology, Catholic University Med School, Rome, Italy
    J Transl Med 10:247. 2012
    ..It is presently unknown whether MM cells express IDO1 and whether IDO1 activity correlates with immune system impairment...
  3. pmc Long-term prospective longitudinal evaluation of emotional distress and quality of life in cervical cancer patients who remained disease-free 2-years from diagnosis
    Giovanna Mantegna
    Psycho Oncology Service, Catholic University, Campobasso, Italy
    BMC Cancer 13:127. 2013
    ..Here, we provide the first 2-years prospective, longitudinal study evaluating emotional distress and QoL in early stage (ECC) and locally advanced (LACC) cervical cancer patients who remained disease-free 2-years from diagnosis...
  4. pmc MiR-200c and HuR in ovarian cancer
    Silvia Prislei
    Laboratory of Antineoplastic Pharmacology, Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome 00168, Italy
    BMC Cancer 13:72. 2013
    ..This study assessed the role of miR-200c as regulator of class III β-tubulin (TUBB3), a factor associated with drug-resistance and poor prognosis in ovarian cancer...
  5. pmc Conservatively treated glassy cell carcinoma of the cervix
    Gabriella Ferrandina
    Department of Oncology, Catholic University, Campobasso, Rome, Italy
    World J Surg Oncol 6:92. 2008
    ..Very little data about the conservative treatment of early stage glassy cell cervical cancer have been reported...
  6. pmc Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures
    Giuseppina Bonanno
    Department of Gynecology, Catholic University Med School, and Department of Blood Transfusion and Cell Therapy, Azienda Ospedaliera S Camillo Forlanini, Rome, Italy
    J Transl Med 8:129. 2010
    ....
  7. pmc Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies
    Giuseppina Bonanno
    Department of Hematology, Catholic University Med, School, Rome, Italy
    J Transl Med 8:114. 2010
    ....
  8. pmc Solitary pancreatic lymph node metastasis from carcinoma of the breast: case report
    Giacomo Corrado
    Gynecologic Oncology Unit, Department of Oncology, Catholic University of the Sacred Heart, L, go A, Gemelli, 1 86100, Campobasso Italy
    Diagn Pathol 5:29. 2010
    ..We report the first case of isolated pancreatic lymph node recurrence in a locally advanced breast cancer patient...
  9. pmc Interleukin-21 induces the differentiation of human umbilical cord blood CD34-lineage- cells into pseudomature lytic NK cells
    Giuseppina Bonanno
    Department of Gynaecology, Catholic University Medical School, Rome, Italy
    BMC Immunol 10:46. 2009
    ..The present study was designed and conducted to address whether IL-21 might replace the stromal cell requirements and foster the IL-15-induced NK differentiation of human UCB CD34-lineage- cells...
  10. pmc Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients
    Francesco Legge
    Gynecologic Oncology Unit, Catholic University of Campobasso, Italy
    BMC Cancer 11:214. 2011
    ..We evaluated the antitumor activity and safety of the combination carboplatin plus the COX-2 inhibitor celecoxib in recurrent heavily-treated OC patients...
  11. pmc CD133 antigen expression in ovarian cancer
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Department of Oncology, Catholic University, Campobasso, Italy
    BMC Cancer 9:221. 2009
    ..The aim of the study was to investigate the clinical role of the immunohistochemically assessed expression of CD133 in a large single Institution series of ovarian cancer patients...
  12. pmc Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial
    Sandro Pignata
    Medical Oncology B, National Cancer Institute, Naples, Italy
    BMC Cancer 6:202. 2006
    ..Due to the paucity of published phase I data on the 3-weekly experimental schedule used, an early safety analysis was planned...
  13. pmc Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome
    Francesco Legge
    Gynecologic Oncology Unit, Department of Oncology, Catholic University of Campobasso, Italy
    BMC Cancer 8:367. 2008
    ..The aim of the study was to retrospectively review ILNR observed in our Institution over the past 11 years in order to investigate: the pattern of disease progression after the first diagnosis of ILNR, and their clinical outcome...
  14. pmc Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study
    Sandro Pignata
    Medical Oncology B, National Cancer Institute, Naples, Italy
    BMC Cancer 6:5. 2006
    ..We retrospectively assessed the prevalence of residual neuropathy in a cohort of patients in clinical remission after first-line carboplatin/paclitaxel for advanced ovarian cancer...